Long-term clinical outcomes and therapeutic benefits of triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy: A case study

European Journal of Ophthalmology

Volumn 17, Issue 3, 2007, Pages 392-398

  Ueno, A ^a   Enaida, H ^a   Hata, Y ^a   Hisatomi, T ^a   Nakamura, T ^a   Mochizuki, Y ^a   Sakamoto, T ^b   Ishibashi, Tatsuro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Long term clinical outcomes; PVR; Triamcinolone acetonide; Vitrectomy

Indexed keywords

EYE DROPS; KENAKOLT A; LATANOPROST; TIMOLOL MALEATE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CILIARY DISK; CLINICAL ARTICLE; CORNEA DISEASE; ELECTRON MICROSCOPY; ENDOPHTHALMITIS; EPIRETINAL MEMBRANE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRAOCULAR PRESSURE; LONG TERM CARE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; EPIRETINAL MEMBRANE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE;

EID: 34447126899     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210701700320     Document Type: Article

References (37)

1. Glaser BM. Surgery of proliferative vitreoretinopathy. In: Ryan SJ, ed. Retina. St. Louis: CV Mosby; 1994: 2265-80.
2. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 1998; 43: 3-18.
3. Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S. Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol 2000; 118: 1116-8.
4. Feron EJ, Veckeneer M, Parys-Van Ginderdeuren R, Van Lommel A, Melles GR, Stalmans P. Trypan blue staining of epiretinal membranes in proliferative vitreoretinopathy. Arch Ophthalmol 2002; 120: 141-4.
5. Li K, Wong D, Hiscott P, Stanga P, Groenewald C, McGalliard J. Trypan blue staining of internal limiting membrane and epiretinal membrane during vitrectomy: visual results and histopathological findings. Br J Ophthalmol 2003; 87: 216-9.
6. Enaida H, Sakamoto T, Hisatomi T, Goto Y, Ishibashi T. Morphological and functional damage of the retina caused by intravitreous indocyanine green in rat eyes. Graefes Arch Clin Exp Ophthalmol 2002; 240: 209-3.
7. Sippy BD, Engelbrecht NE, Hubbard GB, et al. Indocyanine green effect on cultured human retinal pigment epithelial cells: implication for macular hole surgery. Am J Ophthalmol 2001; 132: 433-5.
8. Stalmans P, Van Aken EH, Veckeneer M, Feron EJ, Stalmans I. Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent. Am J Ophthalmol 2002; 134: 282-5.
9. Gandorfer A, Haritoglou C, Gass CA, Ulbig MW, Kampik A. Indocyanine green-assisted peeling of the internal limiting membrane may cause retinal damage. Am J Ophthalmol 2001; 132: 431-3.
10. Haritoglou C, Gandorfer A, Gass CA, Schaumberger M, Ulbig MW, Kampik A. Indocyanine green-assisted peeling of the internal limiting membrane in macular hole surgery affects visual outcome: a clinicopathologic correlation. Am J Ophthalmol 2002; 134: 836-41.
11. Uemura A, Kanda S, Sakamoto Y, Kita H. Visual field defects after uneventful vitrectomy for epiretinal membrane with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 2003; 136: 252-7.
12. Rezai KA, Farrokh-Siar L, Gasyna EM, Ernest JT. Trypan blue induces apoptosis in human retinal pigment epithelial cells. Am J Ophthalmol 2004; 138: 492-5.
13. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002; 240: 423-39.
14. Enaida H, Sakamoto T, Ueno A, et al. Submacular deposition of triamcinolone acetonide after triamcinolone-assisted vitrectomy. Am J Ophthalmol 2003; 135: 243-6.
15. Sonoda KH, Enaida H, Ueno A, et al. Pars plana vitrectomy assisted by triamcinolone acetonide for refractory uveitis: a case series study. Br J Ophthalmol 2003; 87: 1010-4.
16. Enaida H, Hata Y, Ueno A, et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina 2003; 23: 764-70.
17. The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90: 121-5.
18. Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 1987; 94: 327-32.
19. Furino C, Micelli Ferrari T, Boscia F, Cardascia N, Recchimurzo N, Sborgia C. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina 2003; 23: 771-6.
20. Tognetto D, Minutola D, Sanguinetti G, Ravalico G. Anatomical and functional outcomes after heavy silicone oil tamponade in vitreoretinal surgery for complicated retinal detachment: a pilot study. Ophthalmology 2005; 112: 1574-8.
21. Rizzo S, Genovesi-Ebert F, Belting C, Vento A, Cresti F. A pilot study on the use of silicone oil-RMN3 as heavier-than-water endotamponade agent. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1153-7.
22. Hida T, Chandler D, Arena JE, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 101: 190-5.
23. Tano Y, Chandler DB, McCuen BW, et al. Glucocorticosteroid inhibition of intraocular proliferation after injury. Am J Ophthalmol 1981; 91: 184-9.
24. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980; 90: 810-6.
25. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064-7.
26. Yeung CK, Chan KP, Chiang SW, Pang CP, Lam DS. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003; 44: 5293-300.
27. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24-7.
28. Singh IP, Ahmad SI, Yeh D, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004;138: 286-7.
29. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138: 740-3.
30. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-8.
31. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-50.
32. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112: 139-43.
33. Cekic O, Chang S, Tseng JJ, Akar Y, Barile GR, Schiff WM. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005; 139: 993-8.
34. Kivilcim M, Peyman GA, El-Dessouky ES, Kazi AA, Cheema R, Hegazy H. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000; 31: 474-8.
35. Schindler RH, Chandler D, Thresher R, et al. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982; 93: 415-7.
36. Scholes GN, O'Brien WJ, Abrams GW, et al. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985; 103: 1567-9.
37. Sakamoto T, Enaida H, Kubota T, et al. Incidence of acute endophthalmitis after triamcinolone-assisted pars plana vitrectomy. Am J Ophthalmol 2004; 138: 137-8.